# A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

> **NCT03535727** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 48 (actual)

## Conditions studied

- Adenocarcinoma
- Pancreatic Neoplasms
- Neoplasm, Glandular
- Neoplasms
- Neoplasms Pancreatic
- Digestive System Neoplasm
- Endocrine Gland Neoplasms
- Digestive System Disease
- Pancreatic Diseases
- Endocrine System Diseases

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Irinotecan
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03535727
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535727, "A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03535727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*